HAVN Life Sciences Cash Flow Statement

Financials in millions CAD. Fiscal year is May - April.

Millions CAD. Fiscal year is May - Apr.

Fiscal Year	TTM	FY 2022	FY 2021	FY 2020
Period Ending	Jan '23 Jan 31, 2023	Apr '22 Apr 30, 2022	Apr '21 Apr 30, 2021	Apr '20 Apr 30, 2020
Net Income	-15.71	-22.44	-30.38	-0.49
Depreciation & Amortization	0.19	0.58	4.6	-
Asset Writedown & Restructuring Costs	10.2	11.79	-	-
Stock-Based Compensation	0.5	1.92	9.94	-
Other Operating Activities	1.29	0.81	6.02	-0.01
Change in Accounts Receivable	-0.17	-0.11	-0.21	-
Change in Accounts Payable	0.85	-0.05	0.51	0.49
Change in Other Net Operating Assets	0.24	-0.37	-0.92	-0.9
Operating Cash Flow	-2.61	-7.88	-10.42	-0.9
Capital Expenditures	-	-0.1	-0.03	-
Sale of Property, Plant & Equipment	0.03	0.03	-	-
Cash Acquisitions	-	-1.2	-0.35	-
Other Investing Activities	-	-0.76	-0.02	-3
Investing Cash Flow	0.03	-2.03	-0.4	-3
Long-Term Debt Repaid	-	-0.13	-0.03	-
Net Debt Issued (Repaid)	0.11	-0.13	-0.03	-
Issuance of Common Stock	2	2.03	19.8	23.3
Other Financing Activities	-0.35	-0.33	-1.16	-
Financing Cash Flow	1.75	1.56	18.6	23.3
Net Cash Flow	-0.83	-8.35	7.78	19.4
Free Cash Flow	-2.61	-7.98	-10.45	-0.9
Free Cash Flow Margin	-444.52%	-2885.68%	-	-
Free Cash Flow Per Share	-0.37	-1.86	-5.34	-8.65
Levered Free Cash Flow	-0.71	-3.17	2.02	-
Unlevered Free Cash Flow	-0.7	-3.13	2.03	-
Change in Net Working Capital	-0.86	0.54	0.34	-

Updated Apr 4, 2023. Source: S&P Global Market Intelligence. Standard template. Financial Sources.